Intraocular corticosteroids best for treating complications of chronic inflammatory eye condition

Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a clinical trial.

Uveitis is inflammation of the eye originating in the uvea, which includes the iris, ciliary body, and choroid. Photo: NEI

Compared with methotrexate or ranibizumab intravitreal (in-the-eye) injections, the corticosteroid treatment achieved greater reductions in retinal swelling and was the only therapy in the study that improved vision.

“Prior to this study, we didn’t know the best treatment for persistent or recurrent macular edema, a major cause of vision loss in people with uveitis,” said Douglas A. Jabs, M.D., Johns Hopkins Bloomberg School of Public Health, Baltimore, chair of the study. “This trial strongly indicates that repeat intraocular corticosteroid injections are superior to either intravitreal injections of methotrexate or ranibizumab.”

Uveitis is a collection of inflammatory conditions that affect the internal tissues of the eye. Uveitis can affect the front of the eye (anterior uveitis), the middle of the eye (intermediate uveitis), the back of the eye (posterior uveitis), or the front, middle, and back of the eye (panuveitis).

Inflammation in the eye can lead to fluid buildup in the central part of the eye’s light-sensing retina, known as the macula, and decrease vision. This fluid buildup, called macular edema, is a complication of uveitis that often persists or recurs over time, despite uveitis treatment.

Initial treatment for uveitis-related macular edema seeks to control inflammation and reduce the fluid under the retina. While some patients achieve this goal with oral corticosteroids, most patients with macular edema also need intraocular corticosteroid injections.

The dexamethasone intraocular implant is one such treatment. However, intraocular corticosteroids can raise pressure inside the eye. High intraocular pressure is a key risk factor for glaucoma, which can damage the optic nerve and lead to vision loss. Intraocular corticosteroids can also lead to cataract, a clouding of the eye’s lens, which decreases vision.

The clinical trial enrolled 194 participants (225 study eyes) with well-controlled uveitis but persistent or recurrent macular edema. Sixty-five participants received a dexamethasone corticosteroid, 65 participants received methotrexate, and 64 participants received ranibizumab.

The study took place at 33 clinical centers, located across the United States, the United Kingdom, Australia, and India. All participants had previously received at least one intravitreal corticosteroid injection for uveitis-related macular edema.

The injection schedules for each group were based on how each treatment is generally used in clinical practice.

The corticosteroid group participants received one dexamethasone implant injection at baseline and, if the macular edema had not resolved, another injection at eight weeks.

The methotrexate group received one injection at baseline, then repeat injections at four and eight weeks if macular edema did not resolve. The ranibizumab group received injections at baseline, four weeks, and eight weeks, even if their macular edema resolved.

After 12 weeks, all three groups showed reductions in retinal swelling.

Reduction was greatest in the dexamethasone group compared to the other two (35% reduction for corticosteroid; 20% for ranibizumab; 11% for methotrexate). In addition, only the corticosteroid group showed improvement in vision, nearly five letters—about one row on an eye chart.

The corticosteroid group did have more occurrences of mild increases in intraocular pressure, but rises to high levels were infrequent (less 10%) in all three groups.

“Intraocular corticosteroid treatment remains the most effective therapy for uveitis-related macular edema,” said Nisha Acharya, M.D., University of California San Francisco, the lead author of the study.

“The vision gains in participants who received the corticosteroid treatment were very promising.” (National Institutes of Health)

YOU MAY ALSO LIKE

DNA discovery highlights how we maintain healthy blood sugar levels after meals

A study of the DNA of more than 55,000 people worldwide has shed light on how we maintain healthy blood sugar levels after we have eaten, with implications for our understanding of how the process goes wrong in type 2 diabetes.

Mediterranean Diet's Cellular Benefits Unveiled in New Study

A new study led by Stanford School of Medicine researchers has shed light on one of the cellular mechanisms behind the health benefits of the Mediterranean diet, which is known to promote longevity and overall well-being compared to diets high in fast food, meat, and dairy.

Brain signatures for chronic pain identified in a small group of individuals

For the first time, researchers have recorded pain-related data from inside the brain of individuals with chronic pain disorders caused by stroke or amputation (phantom limb pain).

Vigorous exercise not tied to increased risk of adverse events in rare heart condition

Vigorous exercise does not appear to increase the risk of death or life-threatening arrhythmia for people with hypertrophic cardiomyopathy (HCM), according to a study.

Researchers develop model for how the brain acquires essential omega-3 fatty acids

Findings may aid design of targeted drug delivery into the brain and central nervous system.

Problems with ‘pruning’ brain connections linked to adolescent mental health disorders

Problems with the brain’s ability to ‘prune’ itself of unnecessary connections may underlie a wide range of mental health disorders that begin during adolescence.